Unique ID issued by UMIN | UMIN000048899 |
---|---|
Receipt number | R000055308 |
Scientific Title | A clinical study of anti-aging effect for test product |
Date of disclosure of the study information | 2022/09/09 |
Last modified on | 2024/04/17 15:40:52 |
A clinical study of anti-aging effect for test product
A clinical study of anti-aging effect for test product
A clinical study of anti-aging effect for test product
A clinical study of anti-aging effect for test product
Asia(except Japan) |
Not applicable
Dermatology | Adult |
Others
NO
This clinical trial is conducted for the effects of placental-extract cream on skin-aging.
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
kin anti-aging parameters, such as skin hydration, elasticity, lightness, dermal density, sagging, wrinkle and eyebag, are evaluated at baseline, 4 weeks and 8 weeks after treatment.
Assessment of self-questionnaires
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Prevention
Other |
The participants apply the cream containing 1.5% porcine placental extract. The treatment is applied to the participants' whole face, except for the non-treated side of the crow's feet, twice a day in the morning and evening for 8 weeks.
40 | years-old | <= |
60 | years-old | >= |
Female
Korean female participants aged between 40 and 60 with wrinkle on their crow's feet and nasolabial fold; subjects who sign the informed consent of the study; and those who are cooperative and available for follow-up during the study period.
participants who are pregnant, in nursing condition, or planning to become pregnant; participants who are treated with immune-suppressant within one month from the conduct of the study; participants who participated in a previous study without an appropriate intervening period of one month between studies; participants who have sensitive or hypersensitive skin; participants who have damaged skin in or around the test site, which includes sunburn, tattoos, scars, or other disfiguration on the test site; participants who used similar treatment related to the study during the previous three months; participants who had an experience on test site (skin microdermabrasion, Botox and other skin treatment); participants who have chronic disease (diabetes, asthma, or high blood-pressure); participants who have atopic dermatitis; and participants who have any problem, which might interfere with the healing process.
22
1st name | Kentaro |
Middle name | |
Last name | Tsuji |
DHC Corporation
Primary Research Unit Primary Research Group 1
261-0025
Division 2, 2-42 Hamada, Mihama-ku, Chiba
043-275-4811
ktsuji@dhc.co.jp
1st name | Takeshi |
Middle name | |
Last name | Katayoshi |
DHC Corporation
Primary Research Unit Primary Research Group 1
261-0025
Division 2, 2-42 Hamada, Mihama-ku, Chiba
043-275-4811
t-katayoshi@dhc.co.jp
DHC Corporation
Primary Research Unit Primary Research Group 1
DHC Corporation
Primary Research Unit Primary Research Group 1
Self funding
DERMAPRO Ltd.
DERMA B/D, 61, Seocho-daero, Seocho-gu, Seoul, Republic of Korea
+82(0)2-597-5435
dermapro@dermapro.co.kr
NO
2022 | Year | 09 | Month | 09 | Day |
Unpublished
22
No longer recruiting
2021 | Year | 08 | Month | 27 | Day |
2021 | Year | 09 | Month | 02 | Day |
2021 | Year | 09 | Month | 13 | Day |
2021 | Year | 11 | Month | 12 | Day |
2022 | Year | 09 | Month | 09 | Day |
2024 | Year | 04 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055308